NATIONAL: Statement from the Health Products Regulatory Authority on Covid-19 vaccine Astrazeneca

Health Products Regulatory Authority will continue to participate at the European Medicines Agency

COVID-19 Vaccine

NATIONAL: Statement from the Health Products Regulatory Authority on Covid-19 vaccine Astrazeneca

The European Medicines Agency (EMA) has today concluded a review of cases of unusual blood clots, combined with low blood platelets, which have occurred in people vaccinated with the Covid-19 vaccine Astrazeneca (Vaxzevria®). 

The Health Products Regulatory Authority (HPRA) participated in the scientific review of this important safety issue, through participation in the EMAs Pharmacovigilance and Risk Assessment Committee (PRAC).

HPRA is a state agency, which uses its scientific and clinical expertise to review and monitor health products available in Ireland or exported abroad. HPRA's aim is to make sure that health products we regulate are as safe as possible and do what they are intended to do. 

The safety of the public is of the utmost importance, and it is essential that reports of potential safety concerns, even if very rare, are rigorously and swiftly investigated so that the public can be reassured and if required, appropriate action can be taken.

The HPRA highlights in particular the following key aspects of the EMA conclusion:

The reported combination of blood clots and low blood platelets is very rare, and the overall benefits of the vaccine in preventing COVID-19 outweigh the risks of side effects.

Based on a careful review of the available evidence, a causal relationship is considered plausible between vaccination with Vaxzevria® and cases of blood clots in combination with a low blood platelets. Although such adverse reactions are very rare, they exceeded what would be expected in the general population.

No specific risk factors have been identified at this stage, as based on the available evidence, it was not possible to conclude on factors that may predispose a person to develop this side effect. While cases mostly occurred in women under the age of 60 years, this may be explained by other factors, such as the profile of groups vaccinated in the EEA.

Vaxcevria® product information was recently updated to include advice to healthcare professionals and those vaccinated. This includes recommendation to seek immediate medical attention if any of the following signs and symptoms are experienced following vaccination: shortness of breath, chest pain, leg swelling, or persistent abdominal pain. Medical attention should also be immediately sought if severe or persistent headaches or blurred vision after vaccination occurs, or if there is an experience of skin bruising or pinpoint spots beyond the site of vaccination appearing after a few days.

This safety issue will be kept under continuous close review, with new studies and amendments to ongoing studies requested to provide additional information.

As of 7 April, the HPRA has been notified of approximately 2,800 reports of suspected side effects associated with Vaxcevria®, in the context of 204,270 doses administered. Of these, 18 reports describe blood clots or events possibly associated with blood clots. None are of the nature of the very rare blood clots of concern (e.g. cerebral venous sinus thrombosis or splanchnic vein thrombosis or blood clots in combination with low platelets).  An additional small number of cases describing low platelet counts have been received and follow up is ongoing to rule out the presence of blood clots. 

The HPRA highlights the importance of reporting suspected side effects associated with vaccines through the COVID-19 Vaccine Adverse Reaction Report. The reporting rate across all COVID-19 vaccines to the HPRA demonstrates that health care professionals and members of the public are actively reporting suspected side effects, with the rate comparable to other EEA countries.

As for all vaccines, it is possible to experience side effects, the majority of which are known to be mild to moderate.

Covid-19 is a disease itself associated with blood clotting, as well as risk of hospitalisation and death. The overall benefit of vaccination in preventing COVID-19 disease outweighs the risks of known side effects. 

The HPRA will continue to participate at the EMA and engage with NIAC and the Department of Health on this matter.

If you have a story or want to send a photo or video to us please contact the Donegal Live editorial team any time. To contact Donegal Democrat and Donegal People's Press, email editorial@donegaldemocrat.ie To contact Donegal Post, email editor@donegalpost.com To contact Inish Times, email editor@inishtimes.com.

More News

Buy the e-paper of the Donegal Democrat, Donegal People's Press, Donegal Post and Inish Times here for instant access to Donegal's premier news titles.

Keep up with the latest news from Donegal with our daily newsletter featuring the most important stories of the day delivered to your inbox every evening at 5pm.